SLFN12 has previously been associated with various diseases and pathways, including lung adenocarcinoma, triple-negative breast cancer, prostate cancer, T cell activation, and human enterocytic differentiation [2,3,4,6,7,8]. Here, SLFN12 is linked to triple-negative breast carcinoma.